WHAT IS CLAIMED IS:

1. A method for reducing viral budding from a mammalian cell infected by an enveloped virus, comprising contacting said mammalian cell with a sufficient amount of an antibody that binds a TSG101 protein.

2. The method of claim 1, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

3. The method of claim 2, wherein said mammalian cell is a human cell.

4. The method of claim 3, wherein said antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

5. The method of claim 4, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

6. The method of any one of claims 1-5, wherein said antibody is a monoclonal antibody.

7. A method for treating infection by an enveloped virus in a mammal, comprising administering to said mammal a therapeutically effective amount of an antibody that binds a TSG101 protein.

8. The method of claim 7, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

9. The method of claim 8, wherein said mammal is a human.

10. The method of claim 9, wherein said antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

11. The method of claim 10, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

12. The method of any one of claims 7-11, wherein said antibody is a monoclonal antibody.

13. The method of claim 7, further comprising administering to said mammal a therapeutically effective amount of one or more other therapeutic agents.

14. A method for delivering a therapeutic molecule to a mammalian cell infected by an enveloped virus, comprising contacting said mammalian cell with an antibody conjugate, said antibody conjugate comprising an antibody that binds a TSG101 protein conjugated with said therapeutic molecule.

15. The method of claim 14, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

16. The method of claim 15, wherein said mammalian cell is a human cell.

17. The method of claim 16, wherein said antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

18. The method of claim 17, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

19. The method of any one of claims 14-18, wherein said antibody is a monoclonal antibody.

20. A method for treating infection by an enveloped virus in a mammal, comprising administering to said mammal a therapeutically effective amount of an antibody conjugate, said antibody conjugate comprising an antibody that binds a TSG101 protein conjugated with a therapeutic agent.

21. The method of claim 20, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

22. The method of claim 21, wherein said mammal is a human.

23. The method of claim 22, wherein said antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

24. The method of claim 23, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

25. The method of any one of claims 20-24, wherein said antibody is a monoclonal antibody.

26. The method of claim 20, further comprising administering to said mammal a therapeutically effective amount of one or more other therapeutic agents.

27. A method for identifying a mammalian cell infected by an enveloped virus, comprising

(a) contacting cells of a mammal with an antibody conjugate, said antibody conjugate comprising an antibody that binds a TSG101 protein conjugated with a label; and

(b) detecting a cell having said label attached, thereby identifying said cell infected by said enveloped virus.

28. The method of claim 27, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

29. The method of claim 28, wherein said mammal is a human, and wherein said antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

30. The method of claim 29, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

31. The method of any one of claims 27-30, wherein said antibody is a monoclonal antibody.

32. The method of claim 30, wherein said label is fluorescence label, and wherein said cell having said label attached is detected using a fluorescence activated cell sorter.

33. A method for *ex vivo* removal of cells infected by an enveloped virus from a fluid derived from a mammal, comprising

(a) incubating said fluid with a sufficient amount of a TSG101 antibody that binds a TSG101 protein; and

(b) removing cells bound by said TSG101antibody from said fluid.

34. The method of claim 33, wherein said antibody binds the N-terminal or C-terminal region of said TSG101 protein.

35. The method of claim 34, wherein said fluid is blood or serum.

36. The method of claim 34 or 35, wherein said mammal a human.

37. The method of claim 36, wherein said TSG101 antibody binds an epitope comprised in the amino acid region selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3).

38. The method of claim 37, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

39. The method of claim 37, wherein said TSG101 antibody is a monoclonal antibody.

40. The method of claim 34 or 35, wherein said cells bound by said TSG101 antibody are removed using a column comprising an antibody that binds said TSG101 antibody.

41. A method for treating or preventing infection by an enveloped virus in a mammal, comprising administering to said mammal a therapeutically or prophylactically sufficient amount of a vaccine composition, wherein said vaccine composition comprises a polypeptide comprising a TSG101 protein.

42. The method of claim 41, wherein said polypeptide comprises an N-terminal or C-terminal region of said TSG101 protein.

43. The method of claim 42, wherein said mammal is a human.

44. The method of claim 43, wherein said polypeptide comprises amino acid sequence selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID

NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3), or a fragment of at least 5 amino acids thereof.

45. The method of claim 44, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), Marburg virus, and Ebola virus.

46. A method for treating or preventing infection by an enveloped virus in a mammal, comprising administering to said mammal a therapeutically or prophylactically sufficient amount of a DNA vaccine composition, wherein said DNA vaccine composition comprises a polynucleotide molecule encoding a polypeptide comprising a fragment of a TSG101 protein.

47. The method of claim 46, wherein said polynucleotide molecule encoding a polypeptide comprising an N-terminal or C-terminal region of said TSG101 protein.

48. The method of claim 47, wherein said mammal is a human.

49. The method of claim 48, wherein said polypeptide comprises amino acid sequence selected from the group consisting of VRETVNVITLYKDLKPVL (SEQ ID NO:2) and QLRALMQKARKTAGLSDLY (SEQ ID NO:3), or a fragment of at least 5 amino acids thereof.

50. The method of claim 49, wherein said enveloped virus is selected from the group consisting of human immunodeficiency virus type I (HIV-I), human immunodeficiencyvirus type II (HIV-II), Marburg virus, and Ebola virus.